The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...

We recently published a list of the 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts. In this article, we ...

(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Keytruda (pembrolizumab ... The drug is due to lose patent protection in 2028, however, so MSD (known as Merck & Co in the US) has been working to build its oncology pipeline to absorb the ...

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will ...